EG229571 Inhibitors
Tdpoz8, a gene predicted to enable ubiquitin protein ligase binding activity, plays a pivotal role in cellular protein homeostasis by participating in the proteasome-mediated ubiquitin-dependent protein catabolic process. This predicted function suggests its involvement in the targeted degradation of proteins marked for disposal through ubiquitination. Ubiquitin-proteasome system (UPS) is a critical cellular pathway responsible for maintaining the balance of intracellular proteins by selectively degrading damaged or unwanted proteins. Tdpoz8, being active in both the cytoplasm and nucleus, underscores its versatility in modulating cellular processes related to protein turnover. The gene's involvement in ubiquitin protein ligase binding activity implies its role in facilitating the attachment of ubiquitin molecules to substrate proteins, marking them for degradation by the proteasome. Additionally, Tdpoz8's predicted engagement in the regulation of proteolysis further emphasizes its significance in governing the timely degradation of proteins, contributing to cellular maintenance and homeostasis. Located in cytoplasmic ribonucleoprotein granules and the cytosol, Tdpoz8's subcellular localization further indicates its association with key cellular compartments involved in protein degradation processes.
Inhibiting Tdpoz8 involves targeting various components of the ubiquitin-proteasome system (UPS), a complex network responsible for the selective degradation of cellular proteins. Several mechanisms of inhibition can be employed, focusing on disrupting different stages of the UPS. For instance, proteasome inhibitors directly interfere with the final step of protein degradation by blocking the activity of the 26S proteasome, preventing the breakdown of ubiquitinated proteins marked for disposal. By hindering these upstream processes, the availability of substrates for Tdpoz8 is affected, impacting its role in regulating proteasome-mediated ubiquitin-dependent protein catabolic processes. Additionally, deubiquitinase inhibitors like YODA1 and USP7 inhibitors indirectly influence Tdpoz8 by disrupting deubiquitination, a crucial step in the ubiquitin-proteasome system. This multifaceted approach to inhibition highlights the intricate regulatory mechanisms governing Tdpoz8 and underscores the need for a comprehensive understanding of the UPS for effective modulation of its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924, an NEDD8-activating enzyme (NAE) inhibitor, directly interferes with Tdpoz8 by inhibiting the neddylation pathway. By preventing the neddylation of cullin-RING ligases (CRLs), essential components of the ubiquitin-proteasome system, MLN4924 disrupts the protein degradation process and inhibits the predicted proteasome-mediated ubiquitin-dependent protein catabolic process associated with Tdpoz8. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, a proteasome inhibitor, directly targets Tdpoz8 by blocking the 26S proteasome's activity. By preventing the degradation of ubiquitinated proteins, MG132 interferes with the ubiquitin-proteasome system, leading to the accumulation of proteins targeted for degradation by Tdpoz8, thus inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, directly interferes with Tdpoz8 by inhibiting the chymotrypsin-like activity of the 26S proteasome. By preventing the degradation of ubiquitinated proteins, Bortezomib disrupts the ubiquitin-proteasome system, leading to the accumulation of proteins targeted for degradation by Tdpoz8, thereby inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||
NMS-873 | 1418013-75-8 | sc-478803 | 5 mg | $300.00 | ||
NMS-873, a p97 inhibitor, indirectly influences Tdpoz8 by disrupting the ubiquitin-proteasome system. By inhibiting the ATPase activity of p97, a critical regulator of protein degradation, NMS-873 impairs the extraction of ubiquitinated proteins from the endoplasmic reticulum and inhibits the predicted proteasome-mediated ubiquitin-dependent protein catabolic process associated with Tdpoz8. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I, a disruptor of endoplasmic reticulum-associated protein degradation (ERAD), indirectly influences Tdpoz8 by inhibiting ERAD. By blocking the extraction of misfolded proteins targeted for degradation, Eeyarestatin I disrupts the ubiquitin-proteasome system, leading to the accumulation of proteins that would be degraded by Tdpoz8, thus inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||
YODA 1 | 448947-81-7 | sc-507361 | 10 mg | $215.00 | ||
YODA1, an inhibitor of YOD1 deubiquitinase activity, directly influences Tdpoz8 by disrupting deubiquitination. By inhibiting YOD1, which participates in the removal of ubiquitin chains, YODA1 impairs the processing of ubiquitinated proteins targeted for degradation by Tdpoz8, leading to the accumulation of substrates and inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, an autophagy inhibitor, indirectly influences Tdpoz8 by disrupting autophagic degradation. By inhibiting lysosomal function, Chloroquine impairs the fusion of autophagosomes with lysosomes, leading to the accumulation of ubiquitinated proteins that would be degraded by Tdpoz8, thereby inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin, a proteasome inhibitor, directly interferes with Tdpoz8 by inhibiting the chymotrypsin-like activity of the 20S proteasome. By preventing the degradation of ubiquitinated proteins, Epoxomicin disrupts the ubiquitin-proteasome system, leading to the accumulation of proteins targeted for degradation by Tdpoz8, thereby inhibiting the predicted proteasome-mediated ubiquitin-dependent protein catabolic process. | ||||||